127 related articles for article (PubMed ID: 32529857)
1. Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Hoyo-Muñoz A; Gimenez-Manzorro A; Calles A; Osorio S; Herranz-Alonso A; Sanjurjo-Sáez M
Expert Opin Drug Saf; 2020 Aug; 19(8):1041-1048. PubMed ID: 32529857
[TBL] [Abstract][Full Text] [Related]
2. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.
Kim SH; Suh Y; Ah YM; Jun K; Lee JY
Support Care Cancer; 2020 Aug; 28(8):3617-3626. PubMed ID: 31802250
[TBL] [Abstract][Full Text] [Related]
3. Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases.
Prely H; Herledan C; Caffin AG; Baudouin A; Larbre V; Maire M; Schwiertz V; Vantard N; Ranchon F; Rioufol C
J Cancer Res Clin Oncol; 2022 Mar; 148(3):707-718. PubMed ID: 33914124
[TBL] [Abstract][Full Text] [Related]
4. Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea.
Song YK; Oh JM
Support Care Cancer; 2020 Aug; 28(8):3711-3720. PubMed ID: 31820128
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
Ko Y; Tan SL; Chan A; Wong YP; Yong WP; Ng RC; Lim SW; Salim A
Clin Ther; 2012 Aug; 34(8):1696-704. PubMed ID: 22795926
[TBL] [Abstract][Full Text] [Related]
6. Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort.
Beinse G; Reitter D; Segaux L; Carvahlo-Verlinde M; Rousseau B; Tournigand C; Cudennec T; Laurent M; Boudou-Rouquette P; Paillaud E; Canouï-Poitrine F; Caillet P;
J Geriatr Oncol; 2020 May; 11(4):586-592. PubMed ID: 31445850
[TBL] [Abstract][Full Text] [Related]
7. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method.
van Leeuwen RW; Swart EL; Boven E; Boom FA; Schuitenmaker MG; Hugtenburg JG
Ann Oncol; 2011 Oct; 22(10):2334-41. PubMed ID: 21343376
[TBL] [Abstract][Full Text] [Related]
8. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V; Revuelta-Herrero JL; Collado-Borrell R; Marzal-Alfaro B; Gimenez-Manzorro A; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2019 Sep; 18(9):861-868. PubMed ID: 31282227
[No Abstract] [Full Text] [Related]
9. Prevalence of potential drug-drug interactions in outpatients on treatment with parenteral antineoplastic drugs.
Castro-Manzanares M; do Pazo-Oubiña F; Rodríguez-Rincón RM
Int J Clin Pharm; 2019 Dec; 41(6):1429-1433. PubMed ID: 31538281
[TBL] [Abstract][Full Text] [Related]
10. Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study.
Schlichtig K; Dürr P; Dörje F; Fromm MF
Clin Pharmacol Ther; 2021 Oct; 110(4):1075-1086. PubMed ID: 34118065
[TBL] [Abstract][Full Text] [Related]
11. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.
Popa MA; Wallace KJ; Brunello A; Extermann M; Balducci L
J Geriatr Oncol; 2014 Jul; 5(3):307-14. PubMed ID: 24821377
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions of cytostatics with regular medicines in lung cancer patients.
Rompelman FM; Smit AA; Franssen EJ; Crul M
J Oncol Pharm Pract; 2017 Oct; 23(7):483-490. PubMed ID: 27530243
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs.
van Leeuwen RW; Brundel DH; Neef C; van Gelder T; Mathijssen RH; Burger DM; Jansman FG
Br J Cancer; 2013 Mar; 108(5):1071-8. PubMed ID: 23412102
[TBL] [Abstract][Full Text] [Related]
14. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Del Monte-Millán M; Hoyo-Muñoz A; Gómez Martínez-Sagrera P; Revuelta-Herrero JL; Marzal-Alfaro B; Gonzalez-Haba E; López-Tarruella Cobo S; Jerez Gilarranz Y; Herranz A; Sanjurjo M; Martin M
Support Care Cancer; 2021 Aug; 29(8):4673-4681. PubMed ID: 33506273
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy.
Ismail M; Khan S; Khan F; Noor S; Sajid H; Yar S; Rasheed I
BMC Cancer; 2020 Apr; 20(1):335. PubMed ID: 32307008
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents.
Escudero-Vilaplana V; Ribed A; Romero-Jimenez RM; Herranz-Alonso A; Sanjurjo-Saez M
Eur J Cancer Care (Engl); 2017 May; 26(3):. PubMed ID: 26872286
[TBL] [Abstract][Full Text] [Related]
17. Interaction between phytotherapy and oral anticancer agents: prospective study and literature review.
Clairet AL; Boiteux-Jurain M; Curtit E; Jeannin M; Gérard B; Nerich V; Limat S
Med Oncol; 2019 Apr; 36(5):45. PubMed ID: 30993543
[TBL] [Abstract][Full Text] [Related]
18. Targeted cancer therapy: interactions with other medicines.
Conde-Estévez D
Clin Transl Oncol; 2017 Jan; 19(1):21-30. PubMed ID: 27112938
[TBL] [Abstract][Full Text] [Related]
19. Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.
Liewer S; Huddleston AN
Expert Rev Anticancer Ther; 2015 Apr; 15(4):453-64. PubMed ID: 25683755
[TBL] [Abstract][Full Text] [Related]
20. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability.
Lavan AH; O'Mahony D; Buckley M; O'Mahony D; Gallagher P
Oncologist; 2019 Sep; 24(9):e968-e977. PubMed ID: 30833488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
